Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Comparative Effectiveness of Biologic DMARDs in Rheumatoid Arthritis Patients with Inadequate Response to conventional DMARDs: Using a Bayesian Network Meta-analysis

Conventional DMARDs 치료에 실패한 류마티스 관절염 환자에서 Biologic DMARDs의 임상적 효과 비교: 베이지안 네트워크 메타분석

  • Received : 2015.02.23
  • Accepted : 2015.03.14
  • Published : 2015.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Biologic disease-modifying antirheumatic drugs (bDMARDs) extend the treatment choices for rheumatoid arthritis patients with insufficient response or intolerance to conventional DMARDs (cDMARDs). These agents have considerable efficacy compared with conventional DMARDs, but only a few head-to-head comparisons among these agents have been performed. The objective of this systematic review and network meta-analysis (NMA) was to compare the relative efficacy of Certolizumab with conventional DMARD to licensed bDMARD with cDMARD therapy for patients who failed to prior cDMARD treatment under the condition of the reimbursement coverage criteria in Korea. Methods: A systematic review was conducted using MEDLINE and Cochrane library. Key endpoints were the American College of Rheumatology (ACR) responses of 20/50/70 at six months. Bayesian outcomes were calculated as median of treatment effect, probability of the best, Odds Ratio (OR) and probability that OR was greater than one. Results: Compared with other bDMARDs, Certolizumab were associated with higher or comparable ACR response rates; in ACR20, the OR (probability of OR>1) was 2.08 (92.6%) for Adalimumab, 1.86 (85.7%) for Etanercept, 1.89 (79.5%) for Golimumab, 2.36 (92.1%) for Infliximab, 1.79 (87.0%) for Abatacept, 1.74 (80.8%) for Rituximab and 1.82 (86.8%) for Tocilizaumab. In ACR50 and ACR70, the ORs did not present significant differences. Conclusion: Certolizaumab with cDMARD was more effective or comparable than other bDMARDs in patients who failed prior cDMARD treatment.

Keywords

References

  1. Adams R, Walsh C, Veale D, et al. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmacoeconomics 2010;28:477-87. https://doi.org/10.2165/11533010-000000000-00000
  2. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602. https://doi.org/10.1056/NEJMra040226
  3. Miranda LC, Santos H, Ferreira J, et al. Finding Rheumatoid Arthritis Impact on Life (FRAIL Study): economic burden. Acta Reumatol Port 2012;37:134-42.
  4. Yoo DH. Recent Trend in the Treatment of Rheumatoid Arthritis. Journal of the Korean Orthopaedic Association 2010;45:419. https://doi.org/10.4055/jkoa.2010.45.6.419
  5. Cha HS. Persistence with Anti-TNF Therapies in Patients with Rheumatoid Arthritis. J Rheum Dis. 2011;18(4):231-3. https://doi.org/10.4078/jrd.2011.18.4.231
  6. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013.
  7. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75. https://doi.org/10.1136/ard.2009.126532
  8. Health Insurance Review & Assessment Service. http://www.hira.or.kr/dummy.do?pgmid=HIRAA030010000000&cmsurl=/cms/law/03/05/01/1321935_25105.html&subject=[약제] 고시 제2013-183호 요양급여의 적용기준 및 방법에 관한 세부사항 및 질의응답 안내입니다. 09 MAR 2014.
  9. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24. https://doi.org/10.1002/sim.1875
  10. Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:956-64. https://doi.org/10.1111/j.1524-4733.2008.00347.x
  11. review Ct. Clinical and Economic Overview: Biological Response Modifier Agents for Adults with Rheumatoid Arthritis. CADTH Therapeutic Review: Canadian Agency for Drugs and Technologies in Health; 2010.
  12. Guyot P, Taylor PC, Christensen R, et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. J Rheumatol 2012;39:1198-206. https://doi.org/10.3899/jrheum.111345
  13. Orme ME, Macgilchrist KS, Mitchell S, et al. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics 2012;6:429-64.
  14. Peter JV, John P, Graham PL, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008;336:1006-9. https://doi.org/10.1136/bmj.39537.939039.BE
  15. Keystone E, Heijde D, Mason D, Jr., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29. https://doi.org/10.1002/art.23964
  16. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804. https://doi.org/10.1136/ard.2008.101659
  17. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric antitumour necrosis factor á monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. The Lancet 1999;354:1932-9. https://doi.org/10.1016/S0140-6736(99)05246-0
  18. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9. https://doi.org/10.1056/NEJM199901283400401
  19. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
  20. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45. https://doi.org/10.1002/art.10697
  21. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. The Lancet 2004;363:675-81. https://doi.org/10.1016/S0140-6736(04)15640-7
  22. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelvemonth results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-71. https://doi.org/10.1002/art.21201
  23. Combe B, Codreanu C, Fiocco U, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 2006;65:1357-62. https://doi.org/10.1136/ard.2005.049650
  24. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Annals of internal medicine 2006;144:865-76. https://doi.org/10.7326/0003-4819-144-12-200606200-00003
  25. Strand V, Balbir-Gurman A, Pavelka K, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology (Oxford) 2006;45: 1505-13. https://doi.org/10.1093/rheumatology/kel358
  26. Kim HY, Lee SK, Song YW, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR Journal of Rheumatology 2007;10:9-16. https://doi.org/10.1111/j.1479-8077.2007.00248.x
  27. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80. https://doi.org/10.1002/art.23940
  28. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103. https://doi.org/10.1136/ard.2007.080002
  29. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. The Lancet 2008;371:987-97. https://doi.org/10.1016/S0140-6736(08)60453-5
  30. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009;68:789-96. https://doi.org/10.1136/ard.2008.099010
  31. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629-35. https://doi.org/10.1136/ard.2009.119933
  32. Keystone EC, Kavanaugh A, Weinblatt ME, et al. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. J Rheumatol 2011;38:855-62. https://doi.org/10.3899/jrheum.100752
  33. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21. https://doi.org/10.1002/art.30158
  34. Choy E, McKenna F, Vencovsky J, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology (Oxford) 2012;51:1226-34. https://doi.org/10.1093/rheumatology/ker519
  35. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19. https://doi.org/10.1056/NEJMoa1112072
  36. Takeuchi T, Matsubara T, Nitobe T, et al. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol 2013;23:226-35. https://doi.org/10.3109/s10165-012-0668-z
  37. Jang E, Kim D, Ahn J, et al. Methods for Bayesian meta-analysis 2013.
  38. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009:Cd007848.